TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03005717
Drug: Placebo for LIPO-202
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lyophile manufactured to mimic LIPO-202 lyophile.
Study: NCT05428306
Drug: A1: Ibuprofen/Acetaminophen Fixed dose combination (Laboratorios Silanes S.A. de C.V.)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formula : 200 mg/ 500 mg Pharmaceutical Form: Tablet Dosage: 400 mg / 1000 mg (2 tablets) Administration way: oral
Study: NCT05428306
Drug: A2: Ibuprofen (Motrin®, Pfizer S.A. de C.V.)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A2: Pharmaceutical Form: tablet Dosage: 400 mg (1 tablet) Administration way: oral
Study: NCT05428306
Drug: A3: Acetaminophen (Tylenol caplets®, from Janssen-Cilag, S.A. de C.V.)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A3:Pharmaceutical Form: tablet Formula: Acetaminophen 500 mg Dosage: 1000 mg (2 tablets) Administration way: oral
Study: NCT01521793
Drug: QLT091001
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral QLT091001 administered once daily for 7 days
Study: NCT03507569
Drug: RO7017773
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO7017773 will be administered orally. The doses to be tested will be determined by review of PET scan, PK, and safety results from the previous dose level.
Study: NCT04427618
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 10ml normal saline (placebo) given within approximately 10 minutes before skin incision
Study: NCT01322061
Drug: Ascorbic Acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Effervescent,1000mg/tablet, 2000 mg dissolved in 50ml water, the drug will be given once, one hour prior to surgery
Study: NCT00607373
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mL subcutaneous injection once a week for 26 weeks. Subjects weighing less than 50 kg received 0.8 mL subcutaneous injection.
Study: NCT02695420
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet
Study: NCT00983658
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous repeating dose
Study: NCT00556504
Drug: TCM-700C
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An add-on drug to conventional treatment of Hepatitis C
Study: NCT00556504
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, without acting ingredient.
Study: NCT00705549
Drug: Pemetrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexate I.V 500mg/m2 on Day 1
Study: NCT00457457
Drug: UK-369,003
Approvals — FDA: no, EMA: no, PMDA: no
Description: UK 369,003 is a highly selective and potent inhibitor of PDE5. It has increased selectivity for PDE5 over PDE6 (\>80 fold) compared to sildenafil (\~10 fold). Two recently completed trials have shown efficacy for UK-369,003 in treating subjects with ED
Study: NCT02970942
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily administration subcutaneously ( s.c., under the skin)
Study: NCT00594581
Drug: Juvista (avotermin) plus placebo, standard-care (within-subject controls)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal Juvista (avotermin) at 50ng or 200ng per 100μl per linear cm of wound margin
Study: NCT01495806
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: glucose 5 g
Study: NCT01147432
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo IV infusion (saline) to be administered during two of the three treatment periods
Study: NCT04475887
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: see above
Study: NCT01549418
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01353209
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo given daily for twelve months
Study: NCT01283009
Drug: Inactive Substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive Substance will be given in a double-blind fashion for 20 full days. The treatment course includes a bolus dose on the day of randomization, 7 days of full dose (40 mg/day), 7 days of half dose (20 mg/day), and 6 days of tapering doses (12 mg/day and 4 mg/day).
Study: NCT02476539
Drug: Hemay022
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00080444
Drug: rescue medication
Normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants are allowed to take rescue medication throughout for nausea or vomiting. At the discretion of the investigator, participants are provided with a prescription for rescue medications. Recommended rescue medications are: 5-HT3 antagonists, phenothiazines, butyrophenones, benzamides, corticosteroids, benzodiazepines, domperidone, H1-receptor antagonist, and piperazine derivatives.
Study: NCT04422678
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of Care for the Moderate to Severe COVID-19 Pneumonia as per the Egyptian National Protocol by the Ministry of Health.
Study: NCT02406066
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each cohort will have 2 subjects receiving placebo
Study: NCT00931866
Drug: Diclofenac Sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical diclofenac patch applied once daily to area of pain
Study: NCT01982539
Drug: Zipsor®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of Zipsor® (liquid filled capsules) to patients with mild to moderate acute pain: 25 mg/every 6 hours/up to 4 days treament. Drug taken by mouth.
Study: NCT03204734
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine will been given as a sequential treatment who are got benefit in capecitabine-base chemotherapy.
Study: NCT03204734
Drug: endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: endocrine therapy will been given as a sequential treatment who are got benefit in capecitabine-base chemotherapy.Endocrine therapy is determined by the doctor, including any kind of letrozole, anastrozole, exemestane, fulvestrant, tamoxifen, toremifene, combined with or without drugs or surgery in the inhibition of ovarian function.
Study: NCT02822027
Drug: human gamma globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: human gamma globulin for preterm infants with encephalopathy of prematurities
Study: NCT02822027
Drug: non-human gamma globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-human gamma globulin for preterm infants with encephalopathy of prematurities
Study: NCT04553380
Drug: basic insulin
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Initial dose of basic insulin: 0.2U/kg/d.~2. Dose titration regimens: the dose is titrated by increments of 0.07U/kg daily until the fasting blood glucose（FBG）≤7 mmol / L, and if the FBG≤ 3.9mmol/L, the 0.07U/kg is reduced.~3. Injection time: subcutaneous injection before going to bed every night.
Study: NCT02981615
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: one tablet a day, from day 10 to day 28 in every cycle of the 4 first cycles
Study: NCT00796419
Drug: 5% human albumin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of 250 milliliters (mL) 5% human albumin every 8 hours for 5 days
Study: NCT00796419
Drug: 6% hetastarch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of 250mL 6% hetastarch every 8 hours for 5 days
Study: NCT02433522
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01694498
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00865410
Drug: Wellbutrin SR® 150 mg Extended-Release Tablet, single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: B: Active comparator Subjects received GlaxoSmithKline formulated products under fasting conditions
Study: NCT04186637
Drug: ALPN-202
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple dose levels and dose regimens of ALPN-202 will be administered
Study: NCT02351856
Drug: ARRY-371797, p38 inhibitor, oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: multiple dose, single schedule
Study: NCT04000854
Drug: Calcium hydroxide (Calacept)
Normalized name: Calcium Hydroxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-term follow up of pulp regenerative treatment using two different root canal dressings: calcium hydroxide and chlorhexidin digluconate in immature necrotic traumatized incisiors
Study: NCT01509638
Drug: Group 1 Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in this group will receive IV morphine sulfate or Sponsor-approved equivalent via PCA pump, as needed.
Study: NCT00850239
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00701883
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 capsules, once a day for 8 weeks
Study: NCT02378870
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02806206
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of a placebo pill will be given to each study participant just before the ingestion of the capsule endoscopy pill.
Study: NCT00774267
Drug: BZA 20 mg/CE 0.45 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: There was no drug taken during study 3115A1-4000. During the 3115A1-303 study the test article was supplied as baxedoxifene/CE tablets in capsules. Subjects took one capsule orally, once daily at approximately the same time each day on a continuous regimen for 2 years or until early termination from the study.
Study: NCT00774267
Drug: BZA 20 mg/CE 0.625 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: There was no drug taken during study 3115A1-4000. During the 3115A1-303 study the test article was supplied as baxedoxifene/CE tablets in capsules. Subjects took one capsule orally, once daily at approximately the same time each day on a continuous regimen for 2 years or until early termination from the study.
Study: NCT00774267
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: There was no drug taken during study 3115A1-4000. During the 3115A1-303 study the test article was supplied as placebo capsules. Subjects took one capsule orally, once daily at approximately the same time each day on a continuous regimen for 2 years or until early termination from the study.
Study: NCT03130634
Drug: Silymarin
Normalized name: silymarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: During six cycles of FOLFIRI chemotherapy, the patients will take silymarin (150mg) three times daily from day 1 to day 7 during one cycle of treatment.
Study: NCT02654561
Drug: Heparin Sodium
Normalized name: Heparin Sodium
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A bottle solution of Heparin Sodium(2ml:12500IU) is added to 50ml saline and administered i.v. continuously for 24 hours, which last 7 days or until the death or discharge. The same amount of 0.9% saline as the heparin group will be administered in the placebo group.
Study: NCT02282605
Drug: XF-73 nasal gel
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02282605
Drug: Placebo nasal gel
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00345748
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injectio, IV Infusion, Day 1, 15, 29 and every 28 days for 24 weeks
Study: NCT03016494
Drug: DWJ1386 Tab.
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03948646
Drug: Sofpironium Bromide, 15%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active
Study: NCT05091775
Drug: Asacol is used to treat and prevent mild to moderate acute fissure disease
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of two groups after 2 weeks in fissure wound healing, pain relief, pruritus, burning, bleeding, incontinence. Preliminary results of the study show the rate of fissure improvement 6 weeks after treatment, which is observed by clinical examination. Restoration is defined by complete epithelialization of the fissure site without scarring or residual cracks, and the secondary results will be a reduction in the amount of pain and other symptoms.
Study: NCT04803396
Drug: DF2755A
Approvals — FDA: no, EMA: no, PMDA: no
Description: DF2755A was planned to be administered in two different parts:~Part A: Single oral dose administration on D1 according to the randomization (50, 150, 300 and 300 mg oad).~Part B: was planned (100 mg bid, 200 mg bid or 300 mg bid) but not performed (repeated oral administration from Day 1 to Day 14).
Study: NCT03948646
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle gel
Study: NCT01205139
Drug: TMC435
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg capsule once daily for 7 days
Study: NCT01205139
Drug: TMC435 + TDF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg TMC435 capsule + 300 mg TDF tablet, once daily for 7 days
Study: NCT01205139
Drug: TMC435 + TMC278
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg TMC435 capsule + 25 mg TMC278 tablet, once daily for 11 days
Study: NCT01205139
Drug: TMC278
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg tablet once daily for 11 days
Study: NCT01205139
Drug: TMC435
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg capsule once daily for 11 days
Study: NCT01823913
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single oral dose of a combination tablet of amlodipine orotate 10mg and valsartan 160mg
Study: NCT01823913
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single oral dose of a combination tablet of amlodipine besylate 10mg and valsartan 160mg
Study: NCT02190604
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule- oral dose
Study: NCT02190604
Drug: QBW251
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule - oral dose
Study: NCT04409509
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSL312 diluent administered intravenously
Study: NCT00842491
Drug: endostar, cisplatin, capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Product 1: endostar~Dosing schedule: 15mg daily dose, d1-14~Mode of administration: intravenously
Study: NCT00842491
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Product 2: capecitabine~Dosing schedule: 1000mg/m2 bid, days 1-14, every 3 weeks~Mode of administration: orally
Study: NCT01716052
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactulose
Study: NCT01716052
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03544762
Drug: 18F-FES PET
Normalized name: Pet-ema
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18F-FES PET will be performed for each patient. All patients will receive intravenously injection of 5-8 mCi (185-296 MBq) of 18F-FES. PET imaging will be performed on PET/CT system. The 1-frame dynamic data acquisition of thoracic region including the primary tumor will be started immediately after tracer injection. Whole-body PET acquisition from skull base to upper thigh will be started 60 minutes after tracre injection.
Study: NCT02306902
Drug: ANTARA® (fenofibrate)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 130mg, Capsules
Study: NCT01657240
Drug: PRO-118
Approvals — FDA: no, EMA: no, PMDA: no
Description: instill one drop in each eye once a day for 21 days
Study: NCT04338685
Drug: RO7119929
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO7119929 will be administered orally as a capsule
Study: NCT02390869
Drug: R-MANT
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: A) Rituximab 375 mg/sqm on day 1 every 90 days for 8 cycles
Study: NCT00917904
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: dosage form: vaginal gel~frequency: once daily~duration: 6 weeks
Study: NCT03339752
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10 mg tablet
Study: NCT00993941
Drug: Conserved therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral or intravenous administration
Study: NCT00489658
Drug: Eflornithine plus Nifurtimox combination therapy
Normalized name: nifurtimox
DrugBank: Nifurtimox (DB11820)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02350296
Drug: KSL 40 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen lysine salt (KLS) immediate release oral tablets 40 mg, corresponding to 25 mg of ketoprofen free acid. Ketoprofen lysine salt was administered according to the randomisation list and the cross-over design. One (1) tablet of test formulation was administered to the subjects in the morning with 240 mL of still mineral water. Afterwards, no fluid intake was permitted for 2 h. All subjects were under fasting conditions from the evening before investigational product administration (i.e. for at least 10 h, overnight).
Study: NCT02350296
Drug: OKi® 80 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: OKi® 80 mg granules for oral solution (bipartite sachets: each half sachet containing 40 mg of KLS corresponding to 25 mg of ketoprofen free acid). Ketoprofen lysine salt was administered according to the randomisation list and the cross-over design.~The content of half sachet of the reference formulation was dissolved in 190 mL of still mineral water. The subject drank the entire solution immediately. Then the glass was rinsed with 50 mL of still mineral water and the subject drank the rinse immediately. Afterwards, no fluid intake was permitted for 2 h. All subjects were under fasting conditions from the evening before investigational product administration (i.e. for at least 10 h, overnight).
Study: NCT00031278
Drug: CPG 7909
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each 0.01 mg/kg CPG 7909 treatment will consist of a monitored 2-hour infusion given once weekly until disease progression or a maximum of 24 weeks.
Study: NCT00031278
Drug: Herceptin®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herceptin® will be administered at a dose of 2 mg/kg IV according to the Herceptin® package insert
Study: NCT00031278
Drug: CPG 7909
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each 0.04 mg/kg CPG 7909 treatment will consist of a monitored 2-hour infusion given once weekly until disease progression or a maximum of 24 weeks.
Study: NCT00031278
Drug: CPG 7909
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each 0.16 mg/kg CPG 7909 treatment will consist of a monitored 2-hour infusion given once weekly until disease progression or a maximum of 24 weeks.
Study: NCT00031278
Drug: CPG 7909
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each 0.32 mg/kg CPG 7909 treatment will consist of a monitored 2-hour infusion given once weekly until disease progression or a maximum of 24 weeks.
Study: NCT03426995
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered as a matching oral solution or matching capsule to study drug GSK3358699, during Part A and C once daily
Study: NCT00675272
Drug: hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: hydrocortisone 50mg iv. every 6 hours
Study: NCT04505592
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive placebo with concomitant heparin to maintain activated partial thromboplastin time between 2.0 and 2.5 upper limit of normal.
Study: NCT00731302
Drug: aspirin and meloxicam
Normalized name: bupivacaine and meloxicam
Approvals — FDA: no, EMA: no, PMDA: no
Description: aspirin 81 mg daily then aspirin 81 mg plus meloxicam 7.5 mg daily
Study: NCT02042807
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02700893
Drug: atropine + atracurium + sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine bolus: 20 µg/kg Atracurium: 0.3 mg/kg- Possible additional dose of 0.1 mg/kg Sufentanil: 0.1 µg/kg for infants \< 1000g 0.2 µg/kg for infants \> 1000g
Study: NCT01699061
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet administered with a meal twice a day on Day 1
Study: NCT02335411
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral tablets
Study: NCT02568111
Drug: Vehicle Gel
Normalized name: vehicle gel base no.61
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo applied to injection site as specified in the treatment arm. Matching vehicle gel will be provided by Galderma.
Study: NCT00053911
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00053911
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01338311
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mcg twice a day for a total of 7 doses (3.5 days).
Study: NCT01059435
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously or intravenously
Study: NCT01765257
Drug: AZILECT®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01765257
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01153334
Drug: Early intensive rosuvastatin therapy (40 mg for 7days, starting in ER prior to primary PCI)
Normalized name: rosuvastatin 40 MG
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1. Test group: Early intensive rosuvastatin therapy - rosuvastatin 40 mg for pre-PCI loading and 7 days post PCI and 10 mg daily thereafter 2. Control group: Conventional statin therapy - Placebo for pre-PCI loading in ER and rosuvastatin 10 mg daily after primary PCI
Study: NCT01134055
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo eye drops
Study: NCT01437566
Drug: GDC-0941 Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive GDC-0941 matching placebo QD orally from Day 1 or Day 15 of Cycle 1 until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
Study: NCT01437566
Drug: GDC-0980 Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive GDC-0980 matching placebo QD orally from Day 15 of Cycle 1 until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
Study: NCT03792906
Drug: Norepinephrine 6 mcg
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An intravenous bolus of norepinephrine 6 mcg will be administered for management of maternal hypotension.
Study: NCT03792906
Drug: Norepinephrine 10 mcg
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An intravenous bolus of norepinephrine 10 mcg will be administered for management of maternal hypotension.